公开(公告)号：JP2010142239A

公开(公告)日：2010-07-01

申请号：JP2010018766

申请日：2010-01-29

Applicant: Osiris Therapeutics Inc ,  オシリス セラピューティクス,インコーポレイテッド

Inventor： THIEDE MARK A ,  PITTENGER MARK F ,  MBALAVIELE GABRIEL

IPC: C12N5/0789 ,  C12N5/10 ,  A61K35/12 ,  A61K35/28 ,  A61K48/00 ,  A61P43/00 ,  C12N5/0775 ,  C12N5/078

CPC classification number: C12N5/0647 ,  A61K48/00 ,  C12N2500/38 ,  C12N2500/42 ,  C12N2501/39 ,  C12N2502/1305 ,  C12N2502/1358 ,  C12N2503/02 ,  C12N2510/00

Abstract: PROBLEM TO BE SOLVED: To provide a process and composition for maintaining a human hematopoietic stem cell to reduce or eliminate differentiation of a human mesenchymal stem cell into a committed lineage.
SOLUTION: The process is provided for maintaining the human hematopoietic stem cell in co-culture with the human mesenchymal stem cell such that the CD34+/Thy1+ phenotype for the human hematopoietic stem cell is maintained. Furthermore, the composition therefor is provided.
COPYRIGHT: (C)2010,JPO&INPIT

Abstract translation: 要解决的问题：提供用于维持人类造血干细胞以减少或消除人间充质干细胞分化为承诺谱系的方法和组合物。 解决方案：该方法用于维持与人间充质干细胞共培养的人造血干细胞，使得维持人造血干细胞的CD34 + / Thy1 +表型。 此外，提供其组成。 版权所有（C）2010，JPO＆INPIT

公开(公告)号：WO9964565A9

公开(公告)日：2000-04-13

申请号：PCT/US9912847

申请日：1999-06-08

Applicant: OSIRIS THERAPEUTICS INC

Inventor： THIEDE MARK A ,  MBALAVIELE GABRIEL

IPC: A61K35/12 ,  A61K48/00 ,  A61P19/00 ,  C12N5/078 ,  C12N5/06 ,  C12N5/08 ,  C12N5/10

CPC classification number: C12N5/0643 ,  A61K48/00 ,  C12N2500/38 ,  C12N2500/42 ,  C12N2501/39 ,  C12N2502/1358 ,  C12N2503/02 ,  C12N2510/00 ,  C12N2533/18

Abstract: The invention relates to the induction of hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, and, in a preferred embodiment, using no exogenous cytokines. Differentiation of the mesenchymal stem cells into osteoblasts inhibited the differentiation of hematopoietic stem cells into osteoclasts. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate bone resorption.

Abstract translation: 本发明涉及通过用人间充质干细胞培养造血干细胞诱导造血干细胞分化成破骨细胞，并且在优选实施方案中，不使用外源细胞因子。 间充质干细胞向成骨细胞的分化抑制了造血干细胞向破骨细胞的分化。 另外，造血干细胞可以被基因工程改造以携带感兴趣的基因，特别是用于表达生理活性蛋白质。 在间充质干细胞的存在下，转导的细胞携带新的遗传物质并表达可用于调节骨吸收的基因产物。

公开(公告)号：WO9964565A2

公开(公告)日：1999-12-16

申请号：PCT/US9912847

申请日：1999-06-08

Applicant: OSIRIS THERAPEUTICS INC

Inventor： THIEDE MARK A ,  MBALAVIELE GABRIEL

IPC: A61K35/12 ,  A61K48/00 ,  A61P19/00 ,  C12N5/078 ,  C12N5/06 ,  C12N5/08 ,  C12N5/10

CPC classification number: C12N5/0643 ,  A61K48/00 ,  C12N2500/38 ,  C12N2500/42 ,  C12N2501/39 ,  C12N2502/1358 ,  C12N2503/02 ,  C12N2510/00 ,  C12N2533/18

Abstract: The invention relates to the induction of hematopoietic stem cells to differentiate into osteoclasts by culturing hematopoietic stem cells with human mesenchymal stem cells, and, in a preferred embodiment, using no exogenous cytokines. Differentiation of the mesenchymal stem cells into osteoblasts inhibited the differentiation of hematopoietic stem cells into osteoclasts. In addition, hematopoietic stem cells can be genetically engineered to carry genes of interest particularly for the expression of physiologically active proteins. In the presence of mesenchymal stem cells, the transduced cells carry the new genetic material and express gene products that can be used to modulate bone resorption.

Abstract translation: 本发明涉及通过用人间充质干细胞培养造血干细胞诱导造血干细胞分化成破骨细胞，并且在优选的实施方案中，不使用外源细胞因子。 间充质干细胞分化成成骨细胞抑制造血干细胞分化成破骨细胞。 此外，造血干细胞可以被遗传工程化以携带感兴趣的基因，特别是用于表达生理活性蛋白质。 在间充质干细胞的存在下，转导的细胞携带新的遗传物质并表达可用于调节骨吸收的基因产物。

公开(公告)号：CA2271758A1

公开(公告)日：1998-05-22

申请号：CA2271758

申请日：1997-11-13

Applicant: OSIRIS THERAPEUTICS INC

Inventor： MARSHAK DANIEL R ,  THIEDE MARK A

IPC: A01N1/02 ,  A61K35/28 ,  C12N5/0775

Abstract: The present invention is directed to isolated and purified human mesenchymal stem cells, to a method for isolating, purifying, and culturally expanding human mesenchymal stem cells (i.e. mesenchymal stem cells or "MSCs"), and to the characterization of and uses for such cells. In particular, the invention relates to isolation of MSCs that are associated with hematopoietic cells, such as megakaryocyte precursors, in the bone marrow.

公开(公告)号：WO9964566A8

公开(公告)日：2000-02-10

申请号：PCT/US9912851

申请日：1999-06-08

Applicant: OSIRIS THERAPEUTICS INC

Inventor： THIEDE MARK A ,  PITTENGER MARK F ,  MBALAVIELE GABRIEL

IPC: C12N5/10 ,  A61K48/00 ,  C12N5/078 ,  C12N5/0789 ,  C12N5/08

CPC classification number: C12N5/0647 ,  A61K48/00 ,  C12N2500/38 ,  C12N2500/42 ,  C12N2501/39 ,  C12N2502/1305 ,  C12N2502/1358 ,  C12N2503/02 ,  C12N2510/00

Abstract: The present invention is directed to human mesenchymal stem cells isolated from a tissue specimen, such as marrow cells, and to the method of co-culturing isolated mesenchymal stem cells and/or mesenchymal stem cell-derived adipocytes with hematopoietic progenitor cells such that the hematopoietic stem cells retain their phenotype.

Abstract translation: 本发明涉及从诸如骨髓细胞的组织标本分离的人间充质干细胞，以及与造血祖细胞共培养分离的间充质干细胞和/或间充质干细胞来源的脂肪细胞的方法，使得造血 干细胞保留其表型。

公开(公告)号：WO9964566A3

公开(公告)日：2001-04-19

申请号：PCT/US9912851

申请日：1999-06-08

Applicant: OSIRIS THERAPEUTICS INC

Inventor： THIEDE MARK A ,  PITTENGER MARK F ,  MBALAVIELE GABRIEL

IPC: C12N5/10 ,  A61K48/00 ,  C12N5/078 ,  C12N5/0789 ,  C12N5/08

CPC classification number: C12N5/0647 ,  A61K48/00 ,  C12N2500/38 ,  C12N2500/42 ,  C12N2501/39 ,  C12N2502/1305 ,  C12N2502/1358 ,  C12N2503/02 ,  C12N2510/00

Abstract: The present invention is directed to human mesenchymal stem cells isolated from a tissue specimen, such as marrow cells, and to the method of co-culturing isolated mesenchymal stem cells and/or mesenchymal stem cell-derived adipocytes with hematopoietic progenitor cells such that the hematopoietic stem cells retain their phenotype.

Abstract translation: 本发明涉及从诸如骨髓细胞的组织标本分离的人间充质干细胞，以及与造血祖细胞共培养分离的间充质干细胞和/或间充质干细胞来源的脂肪细胞的方法，使得造血 干细胞保留其表型。

公开(公告)号：CY1107121T1

公开(公告)日：2012-10-24

申请号：CY081100007

申请日：2008-01-02

Applicant: OSIRIS THERAPEUTICS INC

Inventor： THIEDE MARK A ,  MBALAVIELE GABRIEL

IPC: A61K35/12 ,  A61K48/00 ,  A61P19/00 ,  C12N5/078 ,  C12N5/10

Abstract: Ηεφεύρεσηαφοράτηδιέγερσηαιματοποιητικώνβλαστικώνκυττάρωνγιαναδιαφοροποιούνταιπροςοστεοκλάστεςμεκαλλιέργειααιματοποιητικώνβλαστικώνκυττάρωνμεανθρώπιναμεσεγχυματικάβλαστικάκύτταρακαισεμιαπροτιμώμενηπραγματοποίηση, χρησιμοποιώνταςμηεξωγενείςκυτοκίνες. Διαφοροποίησητωνμεσεγχυματικώνβλαστικώνκυττάρωνπροςοστεοβλάστεςπαρεμπόδισετηδιαφοροποίησηαιματοποιητικώνβλαστικώνκυττάρωνπροςοστεοκλάστες. Επιπλέον, αιματοποιητικάβλαστικάκύτταραμπορείγενετικάνακατασκευάζονταιγιαναφέρουνγονίδιαπουενδιαφέρουνιδιαιτέρωςγιατηνέκφρασηφυσιολογικώςδραστικώνπρωτεϊνών. Παρουσίαμεσεγχυματικώνβλαστικώνκυττάρων, ταμεταδιεγερμένακύτταραφέρουντονέογενετικόυλικόκαιεκφράζουνγονιδιακάπροϊόντα, ταοποίαμπορείναχρησιμοποιηθούνγιαναρυθμίσουνεπαναρρόφησηοστού.

公开(公告)号：DK1084230T3

公开(公告)日：2008-03-03

申请号：DK99955496

申请日：1999-06-08

Applicant: OSIRIS THERAPEUTICS INC

Inventor： MBALAVIELE GABRIEL ,  THIEDE MARK A

IPC: A61K35/12 ,  A61K48/00 ,  A61P19/00 ,  C12N5/078 ,  C12N5/10

公开(公告)号：AU4336499A

公开(公告)日：1999-12-30

申请号：AU4336499

申请日：1999-06-08

Applicant: OSIRIS THERAPEUTICS INC

Inventor： THIEDE MARK A ,  MBALAVIELE GABRIEL

IPC: A61K35/12 ,  A61K48/00 ,  A61P19/00 ,  C12N5/078 ,  C12N5/06 ,  C12N5/08 ,  C12N5/10

公开(公告)号：CA2329519A1

公开(公告)日：1999-12-16

申请号：CA2329519

申请日：1999-06-08

Applicant: OSIRIS THERAPEUTICS INC

Inventor： THIEDE MARK A ,  PITTENGER MARK F ,  MBALAVIELE GABRIEL

IPC: C12N5/10 ,  A61K48/00 ,  C12N5/078 ,  C12N5/0789 ,  C12N5/08

Abstract: The present invention is directed to human mesenchymal stem cells isolated from a tissue specimen, such as marrow cells, and to the method of coculturing isolated mesenchymal stem cells and/or mesenchymal stem cell-derived adipocytes with hematopoietic progenitor cells such that the hematopoietic stem cells retain their phenotype.